JP2007515399A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007515399A5 JP2007515399A5 JP2006540085A JP2006540085A JP2007515399A5 JP 2007515399 A5 JP2007515399 A5 JP 2007515399A5 JP 2006540085 A JP2006540085 A JP 2006540085A JP 2006540085 A JP2006540085 A JP 2006540085A JP 2007515399 A5 JP2007515399 A5 JP 2007515399A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- hydroxy
- amino
- nitro
- carboxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- -1 hydroxy, sulfhydryl Chemical group 0.000 claims 91
- 125000000623 heterocyclic group Chemical group 0.000 claims 60
- 125000001424 substituent group Chemical group 0.000 claims 55
- 125000005843 halogen group Chemical group 0.000 claims 54
- 229910052717 sulfur Inorganic materials 0.000 claims 46
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 33
- 150000001875 compounds Chemical class 0.000 claims 31
- 125000004093 cyano group Chemical group *C#N 0.000 claims 31
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 31
- 229910052739 hydrogen Inorganic materials 0.000 claims 30
- 239000001257 hydrogen Substances 0.000 claims 30
- 125000002837 carbocyclic group Chemical group 0.000 claims 28
- 229910052760 oxygen Inorganic materials 0.000 claims 28
- 125000003545 alkoxy group Chemical group 0.000 claims 24
- 125000004043 oxo group Chemical group O=* 0.000 claims 24
- 125000005842 heteroatom Chemical group 0.000 claims 22
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 20
- 239000011593 sulfur Substances 0.000 claims 20
- 229910052757 nitrogen Inorganic materials 0.000 claims 18
- 125000005300 thiocarboxy group Chemical group C(=S)(O)* 0.000 claims 18
- 125000002252 acyl group Chemical group 0.000 claims 14
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 12
- 125000006850 spacer group Chemical group 0.000 claims 12
- 150000002431 hydrogen Chemical group 0.000 claims 11
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 10
- 102000043859 Dynamin Human genes 0.000 claims 8
- 108700021058 Dynamin Proteins 0.000 claims 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 claims 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 125000005647 linker group Chemical group 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- LJZUMLIRLJAAGM-UHFFFAOYSA-N (amino-cyano-hydroxy-oxo-lambda6-sulfanyl)formic acid Chemical compound N#CS(O)(=O)(N)C(O)=O LJZUMLIRLJAAGM-UHFFFAOYSA-N 0.000 claims 4
- 101100448208 Human herpesvirus 6B (strain Z29) U69 gene Proteins 0.000 claims 4
- 208000012902 Nervous system disease Diseases 0.000 claims 4
- ZBQQGZCQIIAYIO-UHFFFAOYSA-N OC(=O)[S](O)(=O)C#N Chemical compound OC(=O)[S](O)(=O)C#N ZBQQGZCQIIAYIO-UHFFFAOYSA-N 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 230000001419 dependent effect Effects 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 230000012202 endocytosis Effects 0.000 claims 4
- RVTIGHKQJFRGIF-UHFFFAOYSA-N sulfinoformic acid Chemical compound OC(=O)S(O)=O RVTIGHKQJFRGIF-UHFFFAOYSA-N 0.000 claims 4
- 102000013446 GTP Phosphohydrolases Human genes 0.000 claims 3
- 108091006109 GTPases Proteins 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- BLRCPPIAOOGKDP-UHFFFAOYSA-N 2-benzylidene-3-hydroxybutanedinitrile Chemical group N#CC(O)C(C#N)=CC1=CC=CC=C1 BLRCPPIAOOGKDP-UHFFFAOYSA-N 0.000 claims 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 150000001335 aliphatic alkanes Chemical group 0.000 claims 2
- 239000000539 dimer Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- SMJFNRPDPQQAGL-UHFFFAOYSA-N sulfanylcarbonylsulfanylformic acid Chemical compound OC(=O)SC(O)=S SMJFNRPDPQQAGL-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 108030002935 Dynamin GTPases Proteins 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003906456A AU2003906456A0 (en) | 2003-11-21 | Methods and agents for inhibiting dynamin-mediated endocytosis | |
| AU2003906823A AU2003906823A0 (en) | 2003-12-09 | Methods and agents for inhibiting dynamin-mediated endocytosis II | |
| PCT/AU2004/001624 WO2005049009A1 (en) | 2003-11-21 | 2004-11-22 | Methods and agents for inhibiting dynamin-dependent endocytosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007515399A JP2007515399A (ja) | 2007-06-14 |
| JP2007515399A5 true JP2007515399A5 (https=) | 2008-01-24 |
Family
ID=34620917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006540085A Withdrawn JP2007515399A (ja) | 2003-11-21 | 2004-11-22 | ダイナミン依存エンドサイトーシスを阻害する方法および薬剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20070225363A1 (https=) |
| EP (1) | EP1691800A4 (https=) |
| JP (1) | JP2007515399A (https=) |
| CA (1) | CA2556801A1 (https=) |
| GB (1) | GB2426517A (https=) |
| WO (1) | WO2005049009A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5283962B2 (ja) * | 2007-08-06 | 2013-09-04 | 国立大学法人 岡山大学 | 医薬組成物 |
| EP2192904B1 (en) | 2007-08-27 | 2016-08-17 | Auxagen, Inc. | METHODS FOR INHIBITING TGF-beta |
| GB2458259A (en) * | 2008-02-05 | 2009-09-16 | Univ Aberdeen | Neuroprotective 3-phenylacrylonitrile (3-PAN) derivatives |
| US8487006B2 (en) * | 2008-09-16 | 2013-07-16 | Auxagen, Inc. | Method of enhancing TGF-β signalling |
| EP2432465B1 (en) | 2009-05-21 | 2015-07-22 | Children's Medical Research Institute | Use of dynamin ring stabilizers |
| AU2013334493B2 (en) | 2012-10-26 | 2018-11-29 | The University Of Queensland | Use of endocytosis inhibitors and antibodies for cancer therapy |
| CN109152777A (zh) * | 2016-05-20 | 2019-01-04 | 武田药品工业株式会社 | 疼痛的治疗 |
| US20230142547A1 (en) | 2020-03-20 | 2023-05-11 | Abivax | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
| EP3884946A1 (en) | 2020-03-25 | 2021-09-29 | Abivax | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
| US12275941B2 (en) * | 2021-04-15 | 2025-04-15 | Research Institute At Nationwide Children's Hospital | Products and methods for inhibition of expression of dynamin-1 variants |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5981569A (en) * | 1992-11-13 | 1999-11-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease |
| IL107736A (en) * | 1993-11-24 | 2001-01-11 | Yissum Res Dev Co | Pharmaceutical composition for the prevention of septic shock and for the treatment of chronic inflammatory diseases |
| US5700823A (en) * | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| US5688987A (en) * | 1994-11-09 | 1997-11-18 | Brewer Science, Inc. | Non-subliming Mid-UV dyes and ultra-thin organic arcs having differential solubility |
| US6331555B1 (en) * | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
| US5888481A (en) * | 1995-09-29 | 1999-03-30 | Alliedsignal Inc. | Cinnamamides and their use as stabilizers |
| GB9811692D0 (en) * | 1998-06-01 | 1998-07-29 | Medical Res Council | Improvements in or relating to uptake of substances by cells |
| US20020076784A1 (en) * | 2000-02-28 | 2002-06-20 | Rachel Meyers | 40322, a novel human dynamin |
| WO2003103583A2 (en) * | 2002-06-10 | 2003-12-18 | Oklahoma Medical Research Foundation | A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system |
-
2004
- 2004-11-22 US US10/580,098 patent/US20070225363A1/en not_active Abandoned
- 2004-11-22 EP EP04797072A patent/EP1691800A4/en not_active Withdrawn
- 2004-11-22 CA CA002556801A patent/CA2556801A1/en not_active Abandoned
- 2004-11-22 WO PCT/AU2004/001624 patent/WO2005049009A1/en not_active Ceased
- 2004-11-22 JP JP2006540085A patent/JP2007515399A/ja not_active Withdrawn
- 2004-11-22 GB GB0612313A patent/GB2426517A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2715926T3 (es) | Compuestos para el tratamiento del cáncer | |
| CY1116119T1 (el) | Παραγωγα ισοξαζολο-πυριδινης | |
| CY1122226T1 (el) | Προφαρμακα που περiλαμβανουν συζευγμα εξενδινης αρθρωτη | |
| ES2911040T3 (es) | Nuevos derivados de heteroaril amida como inhibidores selectivos de histona deacetilasa 1 y 2 (HDAC1/2) | |
| JOP20230235A1 (ar) | عقاقير أولية جديدة من الكاتيكولامين للاستخدام في علاج مرض باركنسون | |
| CY1109724T1 (el) | Θειαδιαζολιδινονες ως αναστολεις gsk-3 | |
| CY1113873T1 (el) | Παραγωγα hydroxybenzamide σαν παραγοντες καταστολης της hsp90 | |
| CY1118102T1 (el) | Αλατα διαμινιου φαινοθειαζινης και η χρηση αυτων | |
| JP2016505586A5 (https=) | ||
| EA200501585A1 (ru) | Производные азетидинкарбоксамида и их применение при лечении нарушений, опосредованных св1 рецепторами | |
| JP2013505946A5 (https=) | ||
| JP2018536648A5 (https=) | ||
| AR063872A1 (es) | Derivados de acetileno como inhibidores de estearoil coa desaturasa | |
| EA200870117A1 (ru) | Азаиндоловые ингибиторы аурора-киназ | |
| CY1118390T1 (el) | Θεραπευτικος παραγων για τη φλεγμονωδη νοσο του εντερου | |
| Asirvatham et al. | Privileged scaffold possessing diverse bioactivity profile | |
| MX2010005753A (es) | Derivados de isoxazolo-pirazina. | |
| CN108601952B (zh) | 雷公藤内酯的葡萄糖缀合物、类似物及其用途 | |
| JP2007515399A5 (https=) | ||
| EA200300718A1 (ru) | Производные 3-индолина, которые могут применяться при лечении психиатрических и неврологических расстройств | |
| CY1118229T1 (el) | Ενωση κινολονης και φαρμακευτικη συνθεση | |
| RU2008107733A (ru) | Ингибиторы gsk-3 | |
| JP2006509842A5 (https=) | ||
| CY1116391T1 (el) | Αιθινυλο παραγωγα ως θετικοι αλλοστερικοι ρυθμιστες του mglur5 | |
| JP2018507230A5 (https=) |